Trial · NCT04669366
Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries
NCT04669366, Completed, Pfizer; results first posted 2024-07-19
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries. Trials, record NCT04669366. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04669366
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries
- NCT number
- NCT04669366
- Status
- Completed
- Enrollment
- 1,205 participants, actual
- Lead sponsor
- Pfizer
- Conditions
- Kidney Neoplasms
- Interventions
- sunitinib, axitinib
- First posted
- 2020-12-16
- Last updated
- 2024-07-19
- Results first posted
- 2024-07-19
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With at Least 1 Filled Sunitinib Prescription | Data collected from index date up to 168 months (during retrospective observation period of 14 years, from 01-July-2005 to 31-Dec-2019). Index date was defined as the participant's first identified prescription date | Number of participants who had at least one filled prescription of sunitinib were analyzed and reported in this outcome measure. |
| Primary | Number of Participants With 4:2 Sunitinib Schedule Without Any Modification | Data collected from index date up to 168 months (during retrospective observation period of 14 years, from 01-July-2005 to 31-Dec-2019). Index date was defined as the participant's first identified prescription date | Number of participants that initiated treatment with 4:2 (4 weeks on/2 weeks off) sunitinib schedule and did not have any modification in the schedule were reported in this outcome measure. |
| Primary | Number of Participants With 2:1 Sunitinib Schedule Without Any Modification | Data collected from index date up to 168 months (during retrospective observation period of 14 years, from 01-July-2005 to 31-Dec-2019). Index date was defined as the participant's first identified prescription date | Number of participants that initiated treatment with 2:1 (2 weeks on/1 week off) sunitinib schedule and did not have any modification in the schedule were reported in this outcome measure. |
| Secondary | Number of Participants Switched From 4:2 Sunitinib Schedule to 2:1 Sunitinib Schedule | Data collected from index date up to 168 months (during retrospective observation period of 14 years, from 01-July-2005 to 31-Dec-2019). Index date was defined as the participant's first identified prescription date | Number of sunitinib users that started on a 4:2 (4 weeks on/2 weeks off) schedule and later was switched to a 2:1 (2 weeks on/1 week off) schedule were reported in this outcome measure. |
| Secondary | Number of Participants on Second Line Treatment With at Least 1 Filled Axitinib Prescription | Data collected from index date up to 168 months (during retrospective observation period of 14 years, from 01-July-2005 to 31-Dec-2019). Index date was defined as the participant's first identified prescription date | Number of participants that had at least one filled prescription of axitinib were reported in this outcome measure. |
| Secondary | Time to Treatment Discontinuation (TTD) | Data collected from index date up to 168 months (during retrospective observation period of 14 years, from 01-July-2005 to 31-Dec-2019). Index date was defined as the participant's first identified prescription date | TTD was defined as the difference between the start and end-dates for a treatment episode regardless of reason for discontinuation. The start date for a treatment episode was defined as the date of first dispensed package and the end date was defined as the date of the last dispensed package with the same Anatomical Therapeutic Chemical (ATC) code, plus the number of days that package, as well as accumulated medicine was intended to cover. End date was overruled if there was a new filled prescription of another relevant ATC code or death happens before this, then either of these dates represents the end date. If no end of prescribed supply was recorded, data was censored at latest available date in data. |
| Secondary | Overall Survival (OS) | Data collected from index date up to 168 months (during retrospective observation period of 14 years, from 01-July-2005 to 31-Dec-2019). Index date was defined as the participant's first identified prescription date | OS was defined as the time (number of days) from the start of the treatment (the date of the first dispensed package of Sunitinib or axitinib) until the date of death as documented in the Cause of Death Register. If no death was recorded, data was censored at latest available date in data. |
Source ClinicalTrials.gov
Outcomes7
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With at Least 1 Filled Sunitinib Prescription | Data collected from index date up to 168 months (during retrospective observation period of 14 years, from 01-July-2005 to 31-Dec-2019). Index date was defined as the participant's first identified prescription date | Analysis population included all eligible participants whose data were retrieved from national registries and assessed. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With 4:2 Sunitinib Schedule Without Any Modification | Data collected from index date up to 168 months (during retrospective observation period of 14 years, from 01-July-2005 to 31-Dec-2019). Index date was defined as the participant's first identified prescription date | Analysis population included all eligible participants whose data were retrieved from national registries and assessed. This outcome measure was planned to be analyzed only for Sunitinib 4:2 Schedule reporting group. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With 2:1 Sunitinib Schedule Without Any Modification | Data collected from index date up to 168 months (during retrospective observation period of 14 years, from 01-July-2005 to 31-Dec-2019). Index date was defined as the participant's first identified prescription date | Analysis population included all eligible participants whose data were retrieved from national registries and assessed. This outcome measure was planned to be analyzed only for Sunitinib 2:1 Schedule reporting group. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Switched From 4:2 Sunitinib Schedule to 2:1 Sunitinib Schedule | Data collected from index date up to 168 months (during retrospective observation period of 14 years, from 01-July-2005 to 31-Dec-2019). Index date was defined as the participant's first identified prescription date | Analysis population included all eligible participants whose data were retrieved from national registries and assessed. This outcome measure was planned to be analyzed only for Sunitinib: Switched From 4:2 to 2:1 Schedule reporting group. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants on Second Line Treatment With at Least 1 Filled Axitinib Prescription | Data collected from index date up to 168 months (during retrospective observation period of 14 years, from 01-July-2005 to 31-Dec-2019). Index date was defined as the participant's first identified prescription date | Analysis population included all eligible participants whose data were retrieved from national registries and assessed. This outcome measure was planned to be analyzed only for Axitinib reporting group. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Time to Treatment Discontinuation (TTD) | Data collected from index date up to 168 months (during retrospective observation period of 14 years, from 01-July-2005 to 31-Dec-2019). Index date was defined as the participant's first identified prescription date | Analysis population included all eligible participants whose data were retrieved from national registries and assessed. | Months | MEDIAN |
| SECONDARY | Overall Survival (OS) | Data collected from index date up to 168 months (during retrospective observation period of 14 years, from 01-July-2005 to 31-Dec-2019). Index date was defined as the participant's first identified prescription date | Analysis population included all eligible participants whose data were retrieved from national registries and assessed. | Months | MEDIAN |
Source ClinicalTrials.gov
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With at Least 1 Filled Sunitinib Prescription | Sunitinib 4:2 Schedule | 704 | Participants | ||
| Number of Participants With at Least 1 Filled Sunitinib Prescription | Sunitinib 2:1 Schedule | 320 | Participants | ||
| Number of Participants With at Least 1 Filled Sunitinib Prescription | Sunitinib: Switched From 4:2 to 2:1 Schedule | 71 | Participants | ||
| Number of Participants With at Least 1 Filled Sunitinib Prescription | Axitinib | 53 | Participants | ||
| Number of Participants With 4:2 Sunitinib Schedule Without Any Modification | Sunitinib 4:2 Schedule | 704 | Participants | ||
| Number of Participants With 2:1 Sunitinib Schedule Without Any Modification | Sunitinib 2:1 Schedule | 320 | Participants | ||
| Number of Participants Switched From 4:2 Sunitinib Schedule to 2:1 Sunitinib Schedule | Sunitinib: Switched From 4:2 to 2:1 Schedule | 71 | Participants | ||
| Number of Participants on Second Line Treatment With at Least 1 Filled Axitinib Prescription | Axitinib | 110 | Participants | ||
| Time to Treatment Discontinuation (TTD) | Sunitinib 4:2 Schedule | 4.55 | 95% Confidence Interval 4.3 to 5.6 | Months | |
| Time to Treatment Discontinuation (TTD) | Sunitinib 2:1 Schedule | 6.20 | 95% Confidence Interval 5.6 to 7.2 | Months |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 results by groupParticipant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Sunitinib 4:2 Schedule | 704 | |
| Overall Study | STARTED | Sunitinib 2:1 Schedule | 320 | |
| Overall Study | STARTED | Sunitinib: Switched From 4:2 to 2:1 Schedule | 71 | |
| Overall Study | STARTED | Axitinib | 110 | |
| Overall Study | COMPLETED | Sunitinib 4:2 Schedule | 704 | |
| Overall Study | COMPLETED | Sunitinib 2:1 Schedule | 320 | |
| Overall Study | COMPLETED | Sunitinib: Switched From 4:2 to 2:1 Schedule | 71 | |
| Overall Study | COMPLETED | Axitinib | 110 | |
| Overall Study | NOT COMPLETED | Sunitinib 4:2 Schedule | 0 | |
| Overall Study | NOT COMPLETED | Sunitinib 2:1 Schedule | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Sunitinib 4:2 Schedule | 627 | 704 |
| Total, all-cause mortality | Sunitinib 2:1 Schedule | 168 | 320 |
| Total, all-cause mortality | Sunitinib: Switched From 4:2 to 2:1 Schedule | 53 | 71 |
| Total, all-cause mortality | Axitinib | 82 | 110 |
| Total, other adverse events | Sunitinib 4:2 Schedule | 0 | 0 |
| Total, other adverse events | Sunitinib 2:1 Schedule | 0 | 0 |
| Total, other adverse events | Sunitinib: Switched From 4:2 to 2:1 Schedule | 0 | 0 |
| Total, other adverse events | Axitinib | 0 | 0 |
| Total, serious adverse events | Sunitinib 4:2 Schedule | 0 | 0 |
| Total, serious adverse events | Sunitinib 2:1 Schedule | 0 | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 39057291 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04669366
GET https://conductscience.org/api/trials/v1/NCT04669366/registered